Clik here to view.
Provenge + CT-011 + cyclophosphamide in treatment of mCRPC
The Georgia Health Sciences University in Augusta, GA, has initiated a new trial of sipuleucel-T (Provenge) in combination with cyclophosphamide and an investigational drug known as CT-011 for the...
View ArticleClik here to view.
New data on new and newer drugs at the GU Cancers meeting
A whole host of new data on drugs like sipuleucel-T, enzalutamide, abiraterone, and others was available in the poster sessions at the Genitourinary Cancers Ssympisum in Orlando today. Much of this new...
View ArticleClik here to view.
Drug sequencing and combination therapy with newer prostate cancer therapies
There is an interesting report on the OncLive web site of a lecture by Dr. Robert Dreicer given just a few weeks ago and dealing with the sequential and combination use of new agents like abiraterone...
View ArticleClik here to view.
mCRPC patients with lower PSA levels respond better to sipuleucel-T
According to yet another re-analysis of data from the randomized Phase III trial that led to the original approval of sipuleucel-T (Provenge®), “the … treatment effect appeared greater with decreasing...
View ArticleClik here to view.
Provenge likely to be approved in Europe later this year
The European Medicines Agency’s Committee for Medicinal Products for Human Use today recommended that marketing authorization be approved for sipuleucel-T (Provenge) in the European Union. A final...
View ArticleClik here to view.
Can Dendreon continue on its own?
According to a report on the Bloomberg.com web site, Dendreon “is seeking a buyer after sales of its prostate-cancer treatment failed to meet expectations.” The “New” Prostate Cancer InfoLink has no...
View ArticleClik here to view.
“Immunotherapy for prostate cancer: past, present, and future”
An article with the above title by Dr. Michael Glodé (a well-known medical oncologist at the University of Colorado in Denver) appears in the most recent issue of ASCO Connection. Members of ASCO can...
View ArticleClik here to view.
Dendreon to make sipuleucel-T available in Germany, the UK
According to a media release issued earlier today, Dendreon is planning to make sipuleucel-T (Provenge) available in Europe, beginning with Germany and the United Kingdom. However, the media release is...
View ArticleClik here to view.
NICE rejects Provenge as a treatment for mCRPC based on cost
The National Institute for Health and Clinical Excellence (NICE) in the UK has issued a statement that, according to preliminary draft guidelines, it has rejected the use of sipuleucel-T (Provenge) to...
View ArticleClik here to view.
Provenge to remain available during Dendreon bankruptcy
According to a media release issued by Dendreon Corp. early this morning, the company will be declaring Chapter 11 bankruptcy but is assuring physicians and patients that sipuleucel-T (Provenge) will...
View ArticleClik here to view.
NICE rejects Dendreon’s Provenge … again
According to a report on the PharmaFile web site, the National Institute for Health and Care Excellence (NICE) in England has rejected Dendreon’s application for coverage of the costs of treatment with...
View ArticleClik here to view.
What is going to happen to Dendreon and Provenge?
According to a report on FirstWord Pharma some time yesterday, there are at least two — and maybe more — potential bidders for the assets of Dendreon. The good news for patients is therefore that...
View ArticleClik here to view.
Valeant to acquire assets of Dendreon
According to information on the Reuters web site, Valeant, of Laval, Quebec, is to acquire Seattle-based Dendreon’s sipuleucel-T (Provenge) and other assets for $400 million in cash. Apparently there...
View ArticleClik here to view.
Court clears acquisition of Dendreon by Valeant
After approval by a bankruptcy court judge on Friday, the final acquisition of Dendreon by Valeant Pharmaceuticals is expected to be completed today, ensuring that sipuleucel-T (Provenge) will remain...
View ArticleClik here to view.
Does sequencing of therapy affect outcomes of treatment with sipuleucel-T +...
We still have very little knowledge about whether early prostate cancer immunotherapy with sipuleucel-T (Provenge) or other forms of immunotherapy might be beneficial in the management of patients with...
View ArticleClik here to view.
ADT + sipuleucel-T in treatment of hormone-sensitive prostate cancer
One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease....
View ArticleClik here to view.
The current role of sipuleucel-T in the management of advanced prostate cancer
A new review article has provided a detailed update on the current state of knowledge about the use of sipuleucel-T (Provenge®) in the treatment of advanced forms of prostate cancer. The full text of...
View ArticleClik here to view.
Immunotherapy for the treatment of prostate cancer
The Society for Immunotherapy of Cancer has just issued a detailed statement on the role of immunotherapy in the management of prostate cancer. The full text of this article by McNeel et al. is...
View ArticleClik here to view.
Another new owner for Provenge
According to a media release issued rather quietly a week ago, a large Chinese conglomerate has now bought Provenge (sipuleucel-T) from Valeant, which had acquired it when Valeant bought Dendreon....
View ArticleClik here to view.
Why do African Americans do better on Provenge than whites?
In general, being of African American race is not a good thing when it comes to prostate cancer-related risk (for getting diagnosed with the disease or for outcomes over time). However, … At the...
View Article
